Sukyung Woo PhD

Sukyung Woo

Sukyung Woo
PhD

Associate Professor

Department of Pharmaceutical Sciences

School of Pharmacy


Specialty/Research Focus

Anticancer Drug Development; Cancer Pharmacology; Combination Therapy; Mathematical Modeling; Ovarian Cancer; Pharmacodynamics; Pharmacokinetics; Quantitative Systems PK/PD Relationships; RNAi Therapeutics

Contact Information
352 Pharmacy Building
University at Buffalo
Buffalo, NY 14214
Phone: 716-645-2466
skwoo@buffalo.edu



Professional Summary:

My research utilizes pharmacokinetic/pharmacodynamic and systems pharmacology approaches that integrates a systems perspective, mechanistic mathematical modeling and simulation with quantitative experimental lab studies to advance the discovery, development, and clinical use of drugs.

Education and Training:

  • Postdoctoral Fellow, National Cancer Institute (NCI) (2010)
  • PhD, Pharmaceutical Sciences, State University of New York at Buffalo (2007)
  • MS, Pharmacokinetics, Chungnam National University (2001)
  • BPharm, Pharmacy, Chungnam National University (1999)

Employment:

  • Adjunct Associate Professor, Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center (2020-present)
  • Associate Professor, Pharmaceutical Sciences, University at Buffalo (2019-present)
  • Associate Professor, Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, College of Pharmacy (2017–2019)
  • Investigator, Stephenson Cancer Center at OUHSC (2010–2019)
  • Assistant Professor, Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, College of Pharmacy (2010–2017)
  • Postdoctoral Fellow, Center for Cancer Research, National Cancer Institute, NIH (2008–2010)

Awards and Honors:

  • Edith Kinney Gaylord Presidential Professorship, University of Oklahoma (2019)
  • Research Scholar Award, American Cancer Society (2016)
  • Young Investigator Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism/Clinical Pharmacology Translational Research, AAPS (2013)
  • Cancer Research Training Award Fellowship, Center for Cancer Research, NCI/NIH (2008)
  • Graduate Scholar Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism/Clinical Pharmacology Translational Research Section, AAPS (2007)
  • AAPS Annual Meeting Travels Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) (2006)
  • 2006 Graduate Scholar Award, Pharmaceutical Science, University at Buffalo (2006)
  • Teaching Assistant Award, Pharmaceutical Sciences, University at Buffalo (2004)
  • Dongbu Foundation Scholarship (1997)

Research Expertise:

  • Anticancer drug development, ovarian cancer
  • Pharmacokinetics and Pharmacodynamics
  • Quantitative systems pharmacology (QSP) approaches: integrates a systems perspective, mechanistic mathematical modeling and simulation with quantitative experimental lab studies to advance the discovery, development, and clinical use of drugs.

Grants and Sponsored Research:

  • December 2021–November 2026
    Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition
    NIH-National Cancer Institute (NCI)
    Role: Principal Investigator
    $2,000,000
  • September 2021–August 2022
    Evaluating the Effect of Target Properties on Anti-cancer siRNA Therapeutics
    Center for Protein Therapeutics
    Role: Principal Investigator
    $100,000
  • July 2016–June 2022
    Overcoming resistance to anti-VEGF therapy with predictive modeling
    American Cancer Society
    Role: Principal Investigator
    $792,000
  • June 2016–May 2022
    Targeting HPV Consequences in a Cervical Cancer Clinical Trial
    NIH/NCI
    Role: Co-Investigator
    $2,755,370
  • December 2016–November 2021
    Reprograming Tumor Microenvironment by Nanoparticle
    NIH/NCI
    Role: Co-Investigator
    $1,143,750
  • March 2015–January 2021
    Photo-unclick Chemistry and Its Application to Near Infrared-activatable Prodrugs
    NIGMS/NIH
    Role: Co-Investigator
    $1,784,850
  • August 2017–July 2020
    Visible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder Cancers
    DOD CDMRP/PRCRP
    Role: Co-Investigator
    $529,000
  • July 2015–June 2020
    Ovarian Cancer Chemoprevention
    NCI/NIH
    Role: Co-Investigator
    $3,072,192
  • September 2015–September 2018
    PREVENT Cancer Preclinical Drug Development
    NIH/NCI
    Role: Co-Investigator
    $1,888,965
  • March 2016–June 2017
    Gynecology Oncology Drug Development Fund
    Stephenson Cancer Center
    Role: Principal Investigator
  • September 2012–May 2017
    Tumor resistant mechanisms to anti-VEGF therapy
    NIGMS/NIH
    Role: Principal Investigator
    $612,000
See all (1 more)

Journal Articles:


Professional Memberships:

  • American Society of Clinical Pharmacology and Therapeutics (2013–present)
  • American Association of Cancer Research (2012–present)
  • International Society of Pharmacometrics (2011–present)
  • American Association of Pharmaceutical Scientists (2002–present)

Service Activities:

  • NRG Oncology, Gynecology-Translation Committee; Member (2019–present)
  • Protocol Review and Monitoring Committee (PRMC); Member (2018–2019)
  • Graduate Affairs Committee, Basic Sciences Subcommittee; Chair (2018–2019)
  • Institutional Biosafety Committee (IBC); Member (2017–2019)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

352 Pharmacy Building
University at Buffalo
Buffalo, NY 14214
Phone: 716-645-2466
skwoo@buffalo.edu